Table 1 Patient, disease, and treatment characteristics
Characteristic | Value or number of patients (%) |
|---|---|
Age at allogeneic stem cell transplantation, years | Â |
  Median (range) | 40 (21–69) |
Sex | Â |
  Male | 32 (78 %) |
  Female | 9 (22 %) |
Ethnicity | Â |
  White | 26 (63 %) |
  Hispanic | 10 (24 %) |
  Black | 5 (12 %) |
Diagnosis | Â |
  Acute myeloid leukemia | 9 (22 %) |
  Acute lymphocytic leukemia | 7 (17 %) |
  Acute biphenotypic leukemia | 1 (2 %) |
  Chronic myeloid leukemia | 3 (7 %) |
  Chronic lymphoid leukemia | 1 (2 %) |
  Mantle cell lymphoma | 2 (5 %) |
  Classical Hodgkin lymphoma | 7 (17 %) |
  Mycosis fungoides | 6 (15 %) |
  Diffuse large B-cell lymphoma | 4 (10 %) |
  Peripheral T-cell lymphoma | 1 (2 %) |
Donor | Â |
  Matched unrelated donor | 21 (51 %) |
  Matched related donor | 18 (44 %) |
  Cord blood | 2 (5 %) |
Conditioning regimen | Â |
  Busulfan/fludarabine | 11 (27 %) |
  Busulfan/clofarabine | 5 (12 %) |
  Busulfan/fludarabine/clofarabine | 1 (2 %) |
  Fludarabine/melphalan | 13 (32 %) |
  Fludarabine/melphalan/rituximab | 1 (2 %) |
  Fludarabine/bendamustine/rituximab | 1 (2 %) |
  Fludarabine/bendamustine/ibritumomab | 1 (2 %) |
  Fludarabine/melphalan/alemtuzumab | 2 (5 %) |
  Melphalan/thiotepa/fludarabine/cyclophosphamide | 1 (2 %) |
  Busulfan/clofarabine/gemcitabine | 4 (10 %) |
  Fludarabine/cyclophosphamide/2 Gy TBI | 1 (2 %) |
Time from ASCT to RT, days | Â |
  Median (range) | 299 (45–1715) |
RT dose, Gy | Â |
  Median (range) | 23.4 (2–44) |
Number of RT fractions | Â |
  Median (range) | 12 (1–22) |